GSK’s Mississauga manufacturing operations undergoes $36 M modernization

Site to produce leading topical pain reliever, VOLTAREN

MISSISSAUGA, ON - GSK’s Mississauga manufacturing operations has recently invested $36 million to modernize the site into a world class consumer health and prescription supply site. Commemorated today with a ribbon cutting ceremony, the investment has enabled facility modifications, new equipment purchases, and enhanced manufacturing development capabilities. In addition, funds have supported the transfer in of a well-established Canadian consumer healthcare brand, VOLTAREN.

YS Hong, President, Canada Pharmaceuticals, GSK Canada said, “In addition to contributing to the health and wellness of Canadians through our medicines, vaccines and consumer health products, GSK in Canada is proud to contribute to the local economy. In an increasingly complex and competitive global economic environment, the modernization of our Mississauga manufacturing site demonstrates GSK’s contribution to the retention of well-paying, high skilled jobs in the region and to growing the economy in Ontario.”

Mayor Bonnie Crombie added, “Mississauga is home to a thriving and growing life sciences sector. In fact, we are the only municipality with a life sciences strategy to attract new companies and grow existing businesses. I’m excited about today’s announcement because it means our strategy is working and companies like GSK have the confidence to invest in our City. I want to thank GSK for their investment and for their ongoing partnership as we work to grow this important sector.”

The site currently produces approximately 50 different products, exporting 90% to more than 100 markets worldwide. As a result of the investment, the facility is well positioned to build on its established strengths in the production of complex prescription products with an expanded portfolio of higher volume consumer healthcare products, growing the site’s production capacity from 30 million units a year to almost 50 million units by 2020.

Olivier Keuller, Mississauga Site Director said, “Our combination of a strong market positioning, high-quality products, top talent, and newly enhanced infrastructure is enabling us to attract key consumer health and prescription manufacturing mandates, both now and into the future.”

Commercial production of VOLTAREN, a leading topical pain reliever and the latest addition to the sites production mandate, will begin to be produced for Canada by mid-2019.


VOLTAREN topical gel products are formulated to reduce inflammation and help relieve pain. VOLTAREN products contain the active ingredient diclofenac, a medicine that relieves pain and treats inflammation. Available over the counter in Canada in Original, Extra Strength and Joint Pain varieties.

GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. For further information, please visit

© GSK group of companies or its licensor. Trademarks are owned by or licensed to the GSK group of companies.

Back to top